EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
What Are the Benefits of Implementing a Modern MES in Pharma?
The pharmaceutical sector is rapidly changing in a bid to match the increasing pressure of regulation attain perfection in product quality and hasten the timetomarket A Pharma MES or Manufacturing Execution System is one of the most strategic investments that are strategically placed in this environment in terms of operational excellence
Breaking Down Barriers: Advancements in Biodegradable Drug Delivery
In todays world where sustainability is a top priority breaking down barriers to a greener future is crucial One area where advancements are being made is in the field of biodegradable drug delivery
Cybersecurity in Pharma: The Threat No One Budgeted For
There is a particular kind of risk that organisations are bad at pricing the one that has never happened to them Pharmaceutical companies have spent a generation building sophisticated defences against the risks they know intimatelycontamination adulteration deviation recall Quality systems are mature inspectionready and deeply funded Cyber risk has never enjoyed that status It sat in the IT budge...
From Visibility to Decision Readiness: The Next Phase of Quality Maturity in Pharma
Over the past decade pharmaceutical organisations have made strong progress in both digitising and digitalising quality operations Systems such as laboratory information management systems LIMS manufacturing execution systems MES and electronic quality management systems eQMS have strengthened traceability embedded workflows and enabled real time visibility across quality processes
Why Biopharma is switching to Single-Use Systems: Cost, Quality, and Flexibility
Singleuse biopharma systems have replaced traditional stainlesssteel systems in the biopharmaceutical industry because of a major industry transformation What factors lead the market toward this direction Major factors that drive the industry involve establishing savings from singleuse equipment in pharmaceutical applications
Advancing Pharmacovigilance Talent for AI: Overcoming Skills and Resource Barriers
In the transforming field of pharmacovigilance PV artificial intelligence AI is reshaping how drug safety is monitored and managed As PV evolves from manual reactive workflows to sophisticated AIaugmented systems the imperative for comprehensive workforce upskilling grows stronger Organisations and professionals must adapt to new technical demands regulatory requirements and ethical challenges to...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases
Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Breaking Down Barriers: Advancements in Biodegradable Drug Delivery
Kate Williamson
This article discusses the benefits and advancements in biodegradable drug delivery systems, highlighting their role in improving patient outcomes and reducing environmental impact. It covers the adva...
-
2
Cybersecurity in Pharma: The Threat No One Budgeted For
Lakshmi
Pharma spent a generation hardening itself against contamination and recall—while cyber risk stayed a forgotten IT line item. That framing has collapsed. Today's attackers don't just ste...
-
3
From Visibility to Decision Readiness: The Next Phase of Quality Maturity in Pharma
Kavita Vengurlekar
Pharma companies can now see quality issues much earlier, thanks to digital systems. But faster visibility hasn’t always meant faster decisions. This article explains why the next step in qualit...
-
4
Why Biopharma is switching to Single-Use Systems: Cost, Quality, and Flexibility
Sarah Richards
Single-use systems in the biopharmaceutical field are gaining popularity because they deliver improved quality control features as well as enhanced flexibility combined with cost reductions. Single-us...
-
5
Advancing Pharmacovigilance Talent for AI: Overcoming Skills and Resource Barriers
John Praveen
In the evolving world of pharmacovigilance, artificial intelligence revolutionises drug safety by automating data processing, enhancing signal detection, and enabling real-time risk prediction. Succes...
press releases Read more...
Oorja Bio Announces Initiation of ORBIT-IPF Phase 2 Clinical Trial Evaluating ORJ-001 for the Treatment of Idiopathic Pulmonary Fibrosis
Oorja Bio Inc a clinicalstage biopharmaceutical company developing groundbreaking therapies for fibrotic and cardiopulmonary diseases today announced that the first patient has been screened in its ORBITIPF Phase clinical trial evaluating ORJ for the treatment of idiopathic pulmonary fibrosis
Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise
Tenvie Therapeutics a clinicalstage biotechnology company developing precisionengineered small molecule therapies to transform the treatment of neurological and peripheral diseases today announced the first subject dosed in a Phase clinical study evaluating TNV a fully CNSpenetrant small molecule i...
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Biomea Fusion Inc a clinicalstage biopharmaceutical company today announced that it will report results from its Phase I GLP clinical study evaluating BMF an investigational nextgeneration oral smallmolecule GLP receptor agonist on Tuesday
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Bristol Myers Squibb announced positive topline results from the planned interim analysis of the ACTION trial NCT conducted by RayzeBio Inc a Bristol Myers Squibb company The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progressionfree surv...
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWS Read more...
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics
Enodia Therapeutics announces research and licensing collaboration agreement with Pfizer to develop small molecules directed against Sec61
Enodia Therapeutics a biotech company specializing in the development of innovative therapies with small molecules for the selective degradation of proteins at the point of synthesis today announced the signing of a collaborative research and licensing agreement with Pfizer
Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio
Catalent Inc the leading global contract development and manufacturing organization CDMO dedicated to helping people live better and healthier lives and Mantra a consumer health company developing singleserve over the counter OTC oral gel products for everyday relief
Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase 1 Clinical Trial for Acute Myeloid Leukemia
Amphista Therapeutics Limited a leader in the discovery and development of noncereblon VHL targeted protein degradation TPD medicines today announced dosing of the first patient in a Phase trial for its lead candidate AMX Initiated following authorization from the US Food and Drug Administration i...
Sensible Biotechnologies Secures $47 Million to Advance Cell-Based mRNA Platform
Sensible Biotechnologies has secured million in financing to advance and scale its platform for producing naturally modified messenger RNA mRNA medicines The funding includes a Series A round
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio and TychoBio have entered into a collaboration to generate fulllength RNA data for training artificial intelligence AI models designed to support RNA therapy development for rare diseases



